LONDON--(BUSINESS WIRE)--Apr 29, 2018--Technavio’s latest market research report on the provides an analysis of the most important trends expected to impact the market outlook from 2018-2022. defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180429005093/en/
Technavio has published a new market research report on the global non-insulin diabetes therapeutics market from 2018-2022. (Photo: Business Wire)
According to Technavio market analysts, the global non-insulin diabetes therapeutics market will grow at a CAGR of over 11% during the forecast period. Increasing number of people with type 2 diabetes is a major factor driving the market’s growth. Type 2 diabetes is caused by the body's ineffective use of the insulin produced. It is the most common type of diabetes across the world. Excess body weight and physical inactivity are the most common causes of type 2 diabetes.
In this report, Technavio highlights innovations in therapies as one of the key emerging trends in the global non-insulin diabetes therapeutics market:
Innovations in therapies
Type 2 diabetes reduces the secretion of GLP-1 and reduces responsiveness to glucose-dependent insulinotropic polypeptide (GIP), which are secreted by the GI tract in response to food intake. Both GLP-1 and GIP stimulate the beta cells of the pancreas, which contribute 60% of the insulin secreted after a meal. Several vendors are introducing advanced therapies to treat diabetes such as incretin hormones.
According to a senior analyst at Technavio for research , “The benefits of incretin hormones on glycemic control include enhanced satiety, decreased GI motility, increased glucose-dependent insulin secretion, reduced glucagon secretion, and decreased hepatic glucose release. The pathophysiology of type 2 diabetes involves at least seven organs and tissues, which include the brain, liver, pancreas, intestines, kidneys, fat, and muscles. No single medication addresses all seven organs and tissues. Most people require more than one medication to treat the disease. Hence, drugs with unique and complementary MoA are required. Though all medications are not appropriate for all people, they offer healthcare providers options to individualize treatments and optimize care for patients.”
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Global non-insulin diabetes therapeutics market segmentation
In 2017, DPP4 inhibitor accounted for the largest market share of close to 44%, followed by the other two segments. However, the market share of this segment is expected to witness a significant decrease of close to 15% while that of the other two segments will witness a substantial increase.
Americas held the largest share of the market in 2017, followed by EMEA and APAC. However, the market in APAC will grow faster than the other regions during the forecast period due to improvements in healthcare infrastructure, growing awareness, and the expansion of the operations of several vendors in the region. The market share of the Americas and EMEA will decline due to market maturity.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180429005093/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL RESEARCH DIABETES SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 04/29/2018 07:12 PM/DISC: 04/29/2018 07:12 PM